Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation Indian Medical PG Practice Questions and MCQs

Question 11: Which of the following statements about Menadione (Vitamin K3) is correct?

A. Can cause hemolysis in a patient with G-6-PD deficiency (Correct Answer)
B. Is the preparation of choice to antagonize the effect of warfarin overdose
C. Is useful to prevent hemorrhagic disease of the newborn
D. Is given in large doses in patients with severe liver disease

Explanation: **Explanation:** **Why Option A is Correct:** Menadione (Vitamin K3) is a synthetic, water-soluble analog of Vitamin K. Unlike the natural fat-soluble forms (K1 and K2), Menadione can induce oxidative stress. In patients with **Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency**, the lack of NADPH leads to a failure in maintaining reduced glutathione levels. Menadione triggers the oxidation of hemoglobin, leading to the formation of Heinz bodies and subsequent **hemolysis**. It can also cause neonatal hyperbilirubinemia and kernicterus. **Why Other Options are Incorrect:** * **Option B:** The preparation of choice for warfarin overdose is **Phytonadione (Vitamin K1)**. It acts faster and more reliably than K3. For immediate reversal in life-threatening bleeds, Prothrombin Complex Concentrate (PCC) or Fresh Frozen Plasma (FFP) is used. * **Option C:** Vitamin K1 (Phytonadione) is the standard of care for preventing **Hemorrhagic Disease of the Newborn (HDN)**. Menadione is avoided in neonates due to the risk of hemolysis and brain damage (kernicterus). * **Option D:** In severe liver disease, the liver's synthetic capacity is compromised. Large doses of Vitamin K will not correct the coagulopathy because the "factory" (the liver) cannot utilize the vitamin to produce clotting factors. **High-Yield Clinical Pearls for NEET-PG:** * **Vitamin K Forms:** K1 (Phytonadione - plants), K2 (Menaquinone - bacteria), K3 (Menadione - synthetic). * **Mechanism:** Vitamin K acts as a cofactor for the enzyme **gamma-glutamyl carboxylase**, which activates clotting factors **II, VII, IX, and X** (and proteins C and S). * **Route of Administration:** I.V. Vitamin K1 should be given slowly to avoid **anaphylactoid reactions**. * **Warfarin vs. Heparin:** Vitamin K is the antidote for Warfarin; Protamine sulfate is the antidote for Heparin.

Question 12: Which oral anticoagulant directly inhibits thrombin?

A. Dabigatran (Correct Answer)
B. Dicumarol
C. Warfarin
D. Rivaroxaban

Explanation: **Explanation:** **Correct Option: A. Dabigatran** Dabigatran etexilate is a prodrug that is converted into its active form, which acts as a **Direct Thrombin Inhibitor (DTI)**. Unlike indirect inhibitors (like Heparin), it binds directly to both free and clot-bound thrombin (Factor IIa), preventing the conversion of fibrinogen to fibrin. It is currently the only orally administered DTI approved for clinical use. **Analysis of Incorrect Options:** * **B & C (Dicumarol and Warfarin):** These are **Vitamin K Antagonists (VKAs)**. They act indirectly by inhibiting the enzyme Vitamin K Epoxide Reductase (VKOR), thereby preventing the γ-carboxylation of Vitamin K-dependent clotting factors (II, VII, IX, and X). * **D (Rivaroxaban):** This is a Direct Factor **Xa** inhibitor (along with Apixaban and Edoxaban). A helpful mnemonic is that these drugs have "**xa**" in their name (Riva-**xa**-ban). **High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** The specific reversal agent for Dabigatran is **Idarucizumab** (a monoclonal antibody fragment). * **Monitoring:** Unlike Warfarin, Dabigatran does not require routine INR monitoring. However, if needed, **aPTT** or Ecarin Clotting Time (ECT) can be used to assess its effect. * **Elimination:** It is primarily excreted by the **kidneys** (80%); therefore, it is contraindicated in severe renal failure. * **Clinical Use:** Primarily used for stroke prevention in non-valvular atrial fibrillation and treatment of DVT/PE.

Question 13: Which of the following is the mechanism of action of warfarin?

A. Activation of antithrombin III
B. Fibrinolysis
C. Inhibition of antithrombin III
D. Inhibition of synthesis of clotting factors II, VII, IX, and X (Correct Answer)

Explanation: **Explanation:** **Warfarin** is an oral anticoagulant that acts as a **Vitamin K antagonist**. It works by inhibiting the enzyme **Vitamin K Epoxide Reductase (VKORC1)**. This inhibition prevents the conversion of oxidized Vitamin K back to its active, reduced form (hydroquinone). Active Vitamin K is a mandatory cofactor for the **gamma-carboxylation** of glutamate residues on certain clotting factors. Without this post-translational modification, **Factors II (Prothrombin), VII, IX, and X**, as well as Proteins C and S, are synthesized in an inactive form (known as PIVKAs—Proteins Induced by Vitamin K Absence). Thus, option D is correct. **Analysis of Incorrect Options:** * **Option A & C:** **Antithrombin III (AT-III)** is the target for **Heparin**. Heparin binds to AT-III, accelerating its ability to inactivate Thrombin (IIa) and Factor Xa. Warfarin has no direct interaction with AT-III. * **Option B:** **Fibrinolysis** refers to the breakdown of an existing clot. This is the mechanism of **Thrombolytics** (e.g., Streptokinase, Alteplase), which convert plasminogen to plasmin. Warfarin prevents clot formation but does not dissolve existing ones. **High-Yield NEET-PG Pearls:** * **Monitoring:** Warfarin is monitored using **PT/INR** (Prothrombin Time/International Normalized Ratio). * **Teratogenicity:** It is contraindicated in pregnancy (causes **Fetal Warfarin Syndrome**); Heparin is the drug of choice during pregnancy. * **Warfarin Skin Necrosis:** Occurs due to the rapid depletion of **Protein C** (which has a shorter half-life than factors II, IX, and X), leading to a transient hypercoagulable state. * **Antidote:** For immediate reversal, use **Fresh Frozen Plasma (FFP)** or Prothrombin Complex Concentrate (PCC). For non-emergency reversal, use **Vitamin K1 (Phytonadione)**.

Question 14: Which of the following is used to treat Paroxysmal nocturnal hemoglobinuria?

A. Eculizumab (Correct Answer)
B. Avelumab
C. Natalizumab
D. Sarilumab

Explanation: ### Explanation **Correct Option: A. Eculizumab** Paroxysmal Nocturnal Hemoglobinuria (PNH) is an acquired clonal hematopoietic stem cell disorder characterized by a deficiency of glycosylphosphatidylinositol (GPI) anchored proteins (like CD55 and CD59) on red blood cells. This deficiency makes RBCs highly susceptible to complement-mediated lysis. **Eculizumab** is a humanized monoclonal antibody that binds to the **C5 complement protein**. By inhibiting the cleavage of C5 into C5a and C5b, it prevents the formation of the **Membrane Attack Complex (MAC)**, thereby stopping intravascular hemolysis in PNH patients. **Incorrect Options:** * **B. Avelumab:** A programmed death-ligand 1 (PD-L1) blocking antibody used in the treatment of Merkel cell carcinoma and urothelial carcinoma. * **C. Natalizumab:** An alpha-4 ($\alpha$4) integrin antagonist used primarily in Multiple Sclerosis and Crohn’s disease. It prevents leukocyte adhesion and migration into inflamed tissue. * **D. Sarilumab:** An Interleukin-6 (IL-6) receptor antagonist used in the treatment of moderate-to-severe Rheumatoid Arthritis. **High-Yield Clinical Pearls for NEET-PG:** * **Black Box Warning:** Eculizumab significantly increases the risk of **Meningococcal infections**. Patients must be vaccinated against *Neisseria meningitidis* at least 2 weeks prior to starting therapy. * **Ravulizumab:** A long-acting C5 inhibitor (longer half-life than Eculizumab) also approved for PNH. * **Pegcetacoplan:** A newer agent that targets **C3**, used for patients who still have clinically significant anemia while on C5 inhibitors. * **Triad of PNH:** Hemolytic anemia, Pancytopenia, and Venous thrombosis (Budd-Chiari syndrome is a common complication).

Question 15: What is the recommended route of administration for low molecular weight heparin (LMWH) for thrombosis prophylaxis in a patient who has recently undergone surgery?

A. Subcutaneous (Correct Answer)
B. Intravenous
C. Inhalational
D. Intramuscular

Explanation: ### Explanation **Correct Option: A. Subcutaneous** Low Molecular Weight Heparins (LMWHs), such as Enoxaparin, Dalteparin, and Tinzaparin, are the drugs of choice for perioperative thromboprophylaxis. The **subcutaneous (SC) route** is preferred because LMWHs have high bioavailability (~90%) and a long half-life when administered this way. This allows for predictable pharmacokinetics and once- or twice-daily dosing without the need for routine laboratory monitoring (like aPTT). **Incorrect Options:** * **B. Intravenous (IV):** While Unfractionated Heparin (UFH) is often given as an IV bolus or infusion for immediate anticoagulation (e.g., in PE or MI), LMWH is rarely given IV except in specific protocols like ST-elevation myocardial infarction (STEMI). * **C. Inhalational:** This is not a standard or approved route for heparin delivery due to poor absorption and lack of clinical efficacy. * **D. Intramuscular (IM):** Anticoagulants are **strictly contraindicated** via the IM route because they can cause large, painful, and dangerous **hematomas** at the injection site. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** LMWH acts primarily by inhibiting **Factor Xa** more than Factor IIa (Thrombin), with a ratio of approximately 3:1. * **Monitoring:** Routine monitoring is not required. However, in patients with renal failure, pregnancy, or obesity, **Anti-Xa levels** should be monitored. * **Elimination:** LMWHs are primarily excreted by the **kidneys**; therefore, they are contraindicated or require dose adjustment in patients with renal insufficiency (CrCl <30 ml/min). * **Antidote:** Protamine sulfate only partially neutralizes LMWH (approx. 60%), unlike its complete neutralization of UFH.

Question 16: Clopidogrel is an:

A. Anti-hypertensive
B. Anti-diabetic
C. Anti-platelet (Correct Answer)
D. Anti-coagulant

Explanation: **Explanation:** **Clopidogrel** is a potent **Anti-platelet** agent belonging to the **P2Y12 receptor inhibitors** (Thienopyridine class). It works by irreversibly binding to the P2Y12 adenosine diphosphate (ADP) receptors on the platelet surface. This inhibition prevents the activation of the GPIIb/IIIa receptor complex, thereby inhibiting platelet aggregation and reducing the risk of thrombus formation. **Analysis of Options:** * **Anti-hypertensive (A):** These drugs (e.g., ACE inhibitors, Beta-blockers) lower blood pressure by affecting vascular resistance or cardiac output, not platelet function. * **Anti-diabetic (B):** These agents (e.g., Metformin, Insulin) manage blood glucose levels and have no direct effect on primary hemostasis. * **Anti-coagulant (D):** While both prevent clots, anticoagulants (e.g., Heparin, Warfarin) target the **clotting cascade/fibrin formation**, whereas anti-platelets target **platelet plug formation**. This is a common point of confusion in exams. **High-Yield Clinical Pearls for NEET-PG:** * **Prodrug Status:** Clopidogrel is a **prodrug** that requires activation by the hepatic cytochrome P450 enzyme **CYP2C19**. * **Drug Interaction:** Avoid co-administration with **Omeprazole** (a PPI), as it inhibits CYP2C19, reducing the clinical efficacy of Clopidogrel and increasing the risk of cardiovascular events. * **Clinical Use:** It is a cornerstone therapy for Acute Coronary Syndrome (ACS) and is used in **Dual Antiplatelet Therapy (DAPT)** alongside Aspirin following coronary stent placement. * **Side Effects:** The most significant side effect is bleeding; however, it has a lower risk of GI upset compared to Aspirin. Rare but serious: Thrombotic Thrombocytopenic Purpura (TTP).

Question 17: Dicumarol, a drug that impairs the utilization of vitamin K by the liver, would decrease the plasma concentration of which of the following procoagulants?

A. Prothrombin (Correct Answer)
B. Fibrinogen
C. Antihemophilic factor (factor VIII)
D. Ac-globulin (factor V)

Explanation: **Explanation:** **Mechanism of Action:** Dicumarol is a coumarin derivative (similar to Warfarin) that acts as a competitive inhibitor of the enzyme **Vitamin K Epoxide Reductase (VKOR)**. This enzyme is essential for recycling oxidized Vitamin K back to its reduced form (hydroquinone). Reduced Vitamin K is a mandatory cofactor for the **gamma-carboxylation** of glutamate residues on certain clotting factors. Without this post-translational modification, these factors cannot bind calcium or phospholipid surfaces, rendering them biologically inactive. **Why Prothrombin (Factor II) is Correct:** The Vitamin K-dependent clotting factors are **Factors II (Prothrombin), VII, IX, and X**, as well as proteins C and S. Dicumarol specifically impairs the synthesis of these functional factors. Therefore, it directly decreases the plasma concentration of functional **Prothrombin**. **Why Other Options are Incorrect:** * **B. Fibrinogen (Factor I):** Synthesized in the liver but its production is not dependent on Vitamin K. * **C. Antihemophilic factor (Factor VIII):** A cofactor in the intrinsic pathway; it is not Vitamin K-dependent. * **D. Ac-globulin (Factor V):** A cofactor in the common pathway; its synthesis does not require Vitamin K. **NEET-PG High-Yield Pearls:** * **Mnemonic for Vitamin K factors:** "2, 7, 9, and 10" (often remembered as the year **1972**). * **Shortest Half-life:** Factor VII (first to be depleted; monitored by PT/INR). * **Longest Half-life:** Factor II (Prothrombin). * **Antidote for Coumarin toxicity:** Vitamin K1 (Phytonadione) for gradual reversal; Fresh Frozen Plasma (FFP) or Prothrombin Complex Concentrate (PCC) for immediate reversal. * **Teratogenicity:** Coumarins can cause "Fetal Warfarin Syndrome" (chondrodysplasia punctata), unlike Heparin which does not cross the placenta.

Question 18: Heparin, apart from releasing lipoprotein lipase in the blood, exerts its anticoagulant action by:

A. Binding to calcium
B. Inhibiting fibrinogen synthesis
C. Inhibiting prothrombin synthesis
D. Inhibiting thrombin synthesis (Correct Answer)

Explanation: ### Explanation **1. Why Option D is Correct:** Heparin is an indirect anticoagulant that acts by binding to **Antithrombin III (AT-III)**. This binding induces a conformational change in AT-III, accelerating its ability to inactivate clotting factors, primarily **Thrombin (Factor IIa)** and **Factor Xa**. By inactivating Thrombin, heparin prevents the conversion of fibrinogen to fibrin, effectively "inhibiting thrombin synthesis" (or more accurately, its activation/action) within the coagulation cascade. Additionally, heparin releases **lipoprotein lipase** from the vascular endothelium into the plasma, which helps clear chylomicrons (lipemic clearing action). **2. Why Other Options are Incorrect:** * **Option A (Binding to calcium):** This is the mechanism of **in-vitro anticoagulants** like EDTA, Sodium Citrate, and Oxalate. They chelate calcium (Factor IV), which is essential for multiple steps in the cascade. * **Option B (Inhibiting fibrinogen synthesis):** Fibrinogen is synthesized in the liver. No standard anticoagulant works by stopping its production; heparin only prevents its conversion to fibrin. * **Option C (Inhibiting prothrombin synthesis):** This is the mechanism of **Warfarin (Oral Anticoagulants)**. Warfarin inhibits Vitamin K Epoxide Reductase (VKOR), preventing the synthesis of functional Factors II (Prothrombin), VII, IX, and X. **3. NEET-PG High-Yield Pearls:** * **Monitoring:** Heparin is monitored using **aPTT** (intrinsic pathway). * **Antidote:** **Protamine Sulfate** (a basic drug that neutralizes acidic heparin via chemical antagonism). * **LMWH vs. UFH:** Low Molecular Weight Heparin (e.g., Enoxaparin) mainly inhibits **Factor Xa** and does not require routine aPTT monitoring. * **Side Effect:** Watch for **HIT (Heparin-Induced Thrombocytopenia)**; the drug of choice for HIT is Lepirudin or Argatroban.

Question 19: Low molecular weight dextran is contraindicated in which of the following conditions?

A. Fetal distress syndrome
B. Cerebrovascular accident
C. Electrical burns
D. Thrombocytopenia (Correct Answer)

Explanation: **Explanation:** Low molecular weight dextran (Dextran-40) is a plasma volume expander used to improve microcirculation. However, it is strictly contraindicated in **Thrombocytopenia** and other bleeding disorders. **Why Thrombocytopenia is the Correct Answer:** Dextran-40 interferes with the coagulation cascade and platelet function through several mechanisms: 1. **Platelet Inhibition:** It coats the surface of platelets, reducing their adhesiveness and ability to aggregate. 2. **Factor VIII Interaction:** It reduces the levels of von Willebrand factor (vWF) and Factor VIII complex. 3. **Fibrinolysis:** It alters fibrin structure, making clots more susceptible to lysis. In a patient with a low platelet count (thrombocytopenia), these anti-hemostatic effects significantly increase the risk of severe hemorrhage. **Analysis of Incorrect Options:** * **Fetal distress syndrome:** Dextran is not specifically contraindicated here; in fact, volume expanders may be used in maternal resuscitation to improve placental perfusion. * **Cerebrovascular accident (CVA):** While dextran is avoided in *hemorrhagic* stroke, it was historically used in *ischemic* stroke to decrease blood viscosity and improve cerebral blood flow (though it is no longer first-line). * **Electrical burns:** Dextran-40 is often used in burn management to prevent "sludging" of blood and improve microvascular flow in damaged tissues. **High-Yield Clinical Pearls for NEET-PG:** * **Dextran-40 vs. Dextran-70:** Dextran-40 (LMW) is used to improve microcirculation; Dextran-70 (HMW) is used primarily for volume expansion. * **Acute Renal Failure:** Dextran can cause "Dextran-induced nephrosis" by inducing high tubular viscosity; it is contraindicated in renal insufficiency. * **Anaphylaxis:** Dextran is notorious for causing hypersensitivity reactions. * **Interference with Blood Grouping:** Dextran coats RBCs and can interfere with cross-matching (always draw blood for typing *before* administering dextran).

Question 20: Helmet cells are a characteristic feature of which of the following conditions?

A. G6PD deficiency (Correct Answer)
B. Pyruvate kinase deficiency
C. Pyrimidine 5'-nucleotidase deficiency
D. Adenylate kinase deficiency

Explanation: **Explanation:** **G6PD deficiency** is the correct answer because it is characterized by episodic oxidative stress leading to the formation of **Heinz bodies** (denatured hemoglobin). When these RBCs pass through the splenic sinusoids, splenic macrophages "pluck out" these Heinz bodies. This process results in **"Bite cells"** (Degmacytes). When these bite cells further circulate and undergo fragmentation, they take on a distorted, helmet-like appearance, known as **Helmet cells** (Schistocytes). **Analysis of Incorrect Options:** * **Pyruvate Kinase (PK) Deficiency:** This is the most common enzyme deficiency in the Embden-Meyerhof pathway. It typically presents with **Echinocytes** (Burr cells), which are RBCs with small, uniform, thorny projections, rather than helmet cells. * **Pyrimidine 5'-nucleotidase Deficiency:** This condition is classically associated with prominent **Basophilic stippling** due to the accumulation of ribosomal RNA. It is also a feature of lead poisoning. * **Adenylate kinase Deficiency:** This is a very rare cause of non-spherocytic hemolytic anemia. It does not typically present with specific morphological markers like helmet cells. **NEET-PG High-Yield Pearls:** * **G6PD Inheritance:** X-linked recessive. * **Triggers:** Fava beans, infections, and drugs (Primaquine, Sulfonamides, Nitrofurantoin, Dapsone). * **Morphology Sequence:** Oxidative stress → Heinz bodies (Crystal violet stain) → Bite cells → Helmet cells. * **Key Enzyme:** G6PD is the rate-limiting enzyme of the Hexose Monophosphate (HMP) Shunt, essential for maintaining reduced glutathione to protect RBCs from oxidative damage.

Practice by Chapter

Hematopoietic Growth Factors

Practice Questions

Iron Preparations and Management of Iron Deficiency

Practice Questions

Vitamin B12 and Folic Acid

Practice Questions

Anticoagulants: Heparins and Direct Inhibitors

Practice Questions

Oral Anticoagulants

Practice Questions

Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Hemostatic Drugs

Practice Questions

Plasma Expanders

Practice Questions

Blood Transfusion and Alternatives

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free